Breast Cancer Markers
A method for the detection of the presence of or the risk of cancer in a patient, comprising, with reference to a normal control, the step of: (i) detecting the expression level of a gene characterised by any of the nucleotide sequences identified herein as SEQ ID No. 1 to SEQ ID No. 10, in a sample isolated from a patient, wherein an increased expression level of the gene characterised by any of SEQ ID Nos. 1 to 6 and 10, or a decreased expression level of the gene characterised by any of SEQ ID Nos. 7 to 9, indicates the presence of or the risk of cancer in the patient from whom the sample was isolated.
1 . A method for the detection of the presence of or the risk of cancer in a patient, comprising, with reference to a normal control, the step of:
(i) detecting the expression level of a gene characterised by any of the nucleotide sequences identified herein as SEQ ID No. 1 to SEQ ID No. 10, in a sample isolated from a patient,
wherein an increased expression level of the gene characterised by any of SEQ ID Nos. 1 to 6 and 10, or a decreased expression level of the gene characterised by any of SEQ ID Nos. 7 to 9, indicates the presence of or the risk of cancer in the patient from whom the sample was isolated.
2 . A method according to claim 1 , wherein the sample is isolated from breast tissue.
3 . A method according to claim 1 , wherein the cancer is breast cancer.
4 . A method according to claim 1 , wherein detection is carried out by amplifying the gene using the polymerase enzyme.
5 . An isolated polynucleotide comprising a nucleotide sequence identified herein as any of SEQ ID. Nos. 1 to 10, or its complement, or a polynucleotide of at least 15 consecutive nucleotides that hybridises to any of the sequences (or a complement thereof) under stringent hybridising conditions.
6 . An isolated peptide comprising any of the sequences identified herein as SEQ ID Nos. 11 to SEQ ID No. 20, or a fragment thereof of at least 10 consecutive amino acid residues.
7 . An in vitro diagnostic assay to test for the presence of or the risk of cancer in a patient utilizing an isolated polynucleotide comprising a nucleotide sequence identified herein as any of SEQ ID. Nos. 1 to 10, or its complement, or a polynucleotide of at least 15 consecutive nucleotides that hybridises to any of the sequences (or a complement thereof) under stringent hybridising conditions, or a peptide according to claim 6 .
8 . The method according to claim 7 , wherein the cancer is breast cancer.
9 . An antibody having affinity of at least 10−6M for the peptide of claim 6 .
10 . A method of manufacturing a medicament for the treatment of cancer utilizing a polynucleotide that hybridizes with or inhibits the expression of an endogenous gene that comprises a polynucleotide as defined in claim 5 .
11 . A method according to claim 2 , wherein the cancer is breast cancer.
12 . A method according to claim 2 , wherein detection is carried out by amplifying the gene using the polymerase enzyme.
13 . A method according to claim 3 , wherein detection is carried out by amplifying the gene using the polymerase enzyme.
14 . A method according to claim 11 , wherein detection is carried out by amplifying the gene using the polymerase enzyme.
15 . A method according to claim 10 , wherein the cancer is breast cancer.